An Open Phase Ⅳ Clinical Trial to Evaluate the Immunity Persistence After Single Dose of 23-valent Pneumococcal Polysaccharide Vaccine
Latest Information Update: 18 Aug 2022
At a glance
- Drugs Pneumococcal 23 valent vaccine Sinovac Biotech (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Sponsors Sinovac Biotech
- 10 Aug 2022 Status changed from not yet recruiting to completed.
- 16 Aug 2021 Planned initiation date changed from 30 Jul 2021 to 30 Sep 2021.
- 10 Aug 2021 New trial record